Du ration of Anticoagulant Therapy for Pediatric Venous Thromboembolism

Area of Science:

• Pediatric Hematology
• Vascular Medicine
• Clinical Thrombosis

Background:

• Provoked venous thromboembolism (VTE) is a significant concern in pediatric populations.
• Optimal duration of anticoagulant therapy for provoked VTE in patients under 21 is not well-established.
• Balancing recurrence risk and bleeding risk is crucial in VTE management.

Purpose of the Study:

• To compare the efficacy and safety of a six-week anticoagulant therapy versus a three-month regimen in pediatric patients with provoked VTE.
• To determine noninferiority of shorter-duration anticoagulation.
• To inform clinical guidelines on VTE treatment duration in young patients.

Main Methods:

• A comparative study involving patients younger than 21 years with provoked VTE.
• Patients received anticoagulant therapy for either six weeks or three months.
• Outcomes assessed included recurrent VTE and bleeding events.

Main Results:

• Six weeks of anticoagulant therapy met noninferiority criteria compared to three months.
• The study demonstrated a favorable balance between recurrent VTE risk and bleeding risk with the shorter duration.
• No statistically significant difference in the primary composite outcome was observed.

Conclusions:

• A six-week course of anticoagulant therapy is a viable and noninferior option for pediatric patients with provoked VTE.
• Shorter anticoagulant duration may reduce treatment burden and potential complications.
• These findings support individualized treatment approaches for pediatric VTE.